Loading
Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level.
Andrew Zhu led the liver cancer programme at Massachusetts General Hospital for many years. He was first author of the 2019 Lancet Oncology report of REACH-2, which showed that ramucirumab lengthened survival compared with placebo in previously treated hepatocellular carcinoma with alpha-fetoprotein of 400 ng/mL or more, the first positive phase 3 trial in liver cancer to select patients by a biomarker. He has also led trials of ivosidenib in IDH1-mutant cholangiocarcinoma.
Shares Intrahepatic cholangiocarcinoma, Hepatocellular carcinoma and the tags hcc, biliary, trialist.
Shares Hepatocellular carcinoma and the tags hcc, biliary, trialist.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma and the tags hcc, trialist.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares the tags biliary, trialist.
Shares Hepatocellular carcinoma and the tags hcc, trialist.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Intrahepatic cholangiocarcinoma and the tags biliary, trialist.